Fuente: FierceBiotech Shanghai-based Tenacia Biotechnology is making a $308 million biobucks move for a Rapport Therapeutics asset focused on focal onset seizures and primary generalized tonic-clonic seizures, securing rights to develop and commercialize the candidate in China.